These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 23026947)

  • 41. Membranoproliferative glomerulonephritis in Russian population.
    Dobronravov VA; Smirnov AV
    Ter Arkh; 2018 Dec; 90(12):39-47. PubMed ID: 30701832
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discordant renal histopathologic findings and complement profiles in membranoproliferative glomerulonephritis type III.
    Meyers KE; Strife CF; Witzleben C; Kaplan BS
    Am J Kidney Dis; 1996 Dec; 28(6):804-10. PubMed ID: 8957031
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retinal disease in the C3 glomerulopathies and the risk of impaired vision.
    Savige J; Amos L; Ierino F; Mack HG; Symons RC; Hughes P; Nicholls K; Colville D
    Ophthalmic Genet; 2016 Dec; 37(4):369-376. PubMed ID: 26915021
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.
    Leroy V; Fremeaux-Bacchi V; Peuchmaur M; Baudouin V; Deschênes G; Macher MA; Loirat C
    Pediatr Nephrol; 2011 Mar; 26(3):419-24. PubMed ID: 21188423
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathological features of membranoproliferative glomerulonephritis under a new classification.
    Nargund P; Kambham N; Mehta K; Lafayette RA
    Clin Nephrol; 2015 Dec; 84(6):323-30. PubMed ID: 26445002
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In situ complement activation in porcine membranoproliferative glomerulonephritis type II.
    Jansen JH; Høgåsen K; Harboe M; Hovig T
    Kidney Int; 1998 Feb; 53(2):331-49. PubMed ID: 9461093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toward a working definition of C3 glomerulopathy by immunofluorescence.
    Hou J; Markowitz GS; Bomback AS; Appel GB; Herlitz LC; Barry Stokes M; D'Agati VD
    Kidney Int; 2014 Feb; 85(2):450-6. PubMed ID: 24067430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury].
    Rudnicki M; Windpessl M; Eller K; Odler B; Gauckler P; Neumann I; Zitt E; Regele H; Kronbichler A; Lhotta K; Säemann MD
    Wien Klin Wochenschr; 2023 Aug; 135(Suppl 5):688-695. PubMed ID: 37728653
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.
    Clardy CW; Forristal J; Strife CF; West CD
    Clin Immunol Immunopathol; 1989 Mar; 50(3):333-47. PubMed ID: 2917424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.
    Salvadori M; Rosso G
    World J Nephrol; 2016 Jul; 5(4):308-20. PubMed ID: 27458560
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN.
    Wong EK; Anderson HE; Herbert AP; Challis RC; Brown P; Reis GS; Tellez JO; Strain L; Fluck N; Humphrey A; Macleod A; Richards A; Ahlert D; Santibanez-Koref M; Barlow PN; Marchbank KJ; Harris CL; Goodship TH; Kavanagh D
    J Am Soc Nephrol; 2014 Nov; 25(11):2425-33. PubMed ID: 24722444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
    Togarsimalemath SK; Sethi SK; Duggal R; Le Quintrec M; Jha P; Daniel R; Gonnet F; Bansal S; Roumenina LT; Fremeaux-Bacchi V; Kher V; Dragon-Durey MA
    Kidney Int; 2017 Oct; 92(4):876-887. PubMed ID: 28729035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experimental models of membranoproliferative glomerulonephritis, including dense deposit disease.
    Vernon KA; Pickering MC; Cook T
    Contrib Nephrol; 2011; 169():198-210. PubMed ID: 21252520
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [An approach to research on nephritic factor and membranoproliferative glomerulonephritis].
    Ohi H
    Nihon Jinzo Gakkai Shi; 2012; 54(7):1006-15. PubMed ID: 23234212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
    Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Idiopathic membranoproliferative glomerulonephritis: does it exist?
    Fervenza FC; Sethi S; Glassock RJ
    Nephrol Dial Transplant; 2012 Dec; 27(12):4288-94. PubMed ID: 22798508
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease).
    Abrera-Abeleda MA; Nishimura C; Smith JL; Sethi S; McRae JL; Murphy BF; Silvestri G; Skerka C; Józsi M; Zipfel PF; Hageman GS; Smith RJ
    J Med Genet; 2006 Jul; 43(7):582-9. PubMed ID: 16299065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Changes in the complement system in membranoproliferative glomerulonephritis].
    Yurova VA; Bobrova LA; Kozlovskaya NL; Korotchaeva YV; Serova AG; Kozlov LV; Andina SS; Demyanova KA; Kuchieva AM; Roshchupkina SV
    Ter Arkh; 2017; 89(6):69-77. PubMed ID: 28745692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-complement therapy for glomerular diseases.
    Bomback AS
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.